Leading Avista Capital Partners as Co-CEO and Co-founder, Thompson Dean focuses on diverse health sector investments. Among the companies within Thompson Dean’s corporate portfolio is Osmotica Pharmaceuticals, PLC, which stands as a fully integrated pharmaceutical and generics enterprise that provides solutions in the areas of pain, neuroscience, and women’s health care.
In May 2019, Osmotica announced the positive topline results of its second Phase III safety and efficacy clinical trial involving RVL (oxymetazoline hydrochloride ophthalmic solution, 0.1 percent). The positive topline results also applied to the long-term Phase III safety study for ptosis (droopy eyelid) treatment.
The topline readout was described as being consistent with the results of previous studies and continues to demonstrate administration of the once-daily drop generates statistically significant visual field improvement among patients.
The plan is to submit to the U.S. Food and Drug Administration a New Drug Application that could enable the product to reach pharmacies by mid-2020. The market need is significant, as there is currently no pharmacologic intervention for the condition that is FDA approved.
In May 2019, Osmotica announced the positive topline results of its second Phase III safety and efficacy clinical trial involving RVL (oxymetazoline hydrochloride ophthalmic solution, 0.1 percent). The positive topline results also applied to the long-term Phase III safety study for ptosis (droopy eyelid) treatment.
The topline readout was described as being consistent with the results of previous studies and continues to demonstrate administration of the once-daily drop generates statistically significant visual field improvement among patients.
The plan is to submit to the U.S. Food and Drug Administration a New Drug Application that could enable the product to reach pharmacies by mid-2020. The market need is significant, as there is currently no pharmacologic intervention for the condition that is FDA approved.
